<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:8pt Arial, sans-serif; }
 .font1 { font:10pt Arial, sans-serif; }
 .font2 { font:18pt Arial, sans-serif; }
 .font3 { font:15pt Times New Roman, serif; }
 .font4 { font:23pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font2">This document is being provided for the exclusive use of PORTFOLIO MANAGEMENT CLUB at UNIVERSIDADE NOVA DE LISBOA.</span></p>
<div>
<p><span class="font0">Richard Vosser</span></p>
<p><span class="font0">(44-20) 7742-6652</span></p>
<p><a href="mailto:richard.vosser@jpmorgan.com"><span class="font0">richard.vosser@jpmorgan.com</span></a></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">Europe Equity Research</span></p>
<p><span class="font0">24 February 2023</span></p>
</div><br clear="all">
<div>
<p><span class="font4">J.P. Morgan</span></p>
</div><br clear="all">
<ul style="list-style:none;"><li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;ACIPWorking Group survey indicated that 70% of mothers surveyed would opt for a nirsevimab injection for their infant. </span><span class="font3">A survey of 523 people who were actively pregnant or pregnant within the last 12 months found that 70% of mothers would be inclined to nirsevimab immunisation.</span></p></li></ul>
<p><span class="font1">2</span></p>
</body>
</html>